SCHEMBL98371

SCHEMBL98371

COc1ccc(N)cc1C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.73
KDM4E B2RXH2 6/20 0.55
MAPT P10636 4/20 0.55
TDP1 Q9NUW8 3/20 0.55
HPGD P15428 3/20 0.55
HSD17B10 Q99714 3/20 0.55
MEN1 O00255 2/20 0.55
THRB P10828 2/20 0.55
RECQL P46063 2/20 0.55
KMT2A Q03164 2/20 0.55
CYP3A4 P08684 2/20 0.55
POLB P06746 2/20 0.55
USP2 O75604 1/20 0.55
PKM P14618 1/20 0.55
APEX1 P27695 1/20 0.55
BLM P54132 1/20 0.55
MCL1 Q07820 1/20 0.55
TNF P01375 1/20 0.55
HSPD1 P10809 1/20 0.55
CYP2C9 P11712 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorobenzene SCHEMBL27701192 0.89 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTTDP1HPGD
SCHEMBL3884423 0.85 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHSD17B10USP2
SCHEMBL623759 0.85 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL98089 0.85 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTTDP1HPGD
SCHEMBL31295589 0.85 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL711924 0.84 KDM4E (0.59) ALDH1A1KDM4EMAPTTDP1HPGD
Hydrochloric Acid SCHEMBL25217998 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTTDP1HSD17B10
SCHEMBL570110 0.83 GAA (0.61) ALDH1A1KDM4EMAPTHPGDHSD17B10
Hydrochloric Acid SCHEMBL31095289 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTTDP1HSD17B10
Hydrochloric Acid SCHEMBL15486584 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTTDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118866163-A Novel HDAC11 inhibitor synthesized based on structural design by AlphaFold model 江苏祥澜医疗科技有限公司 2024-10-29 CN claimed
US-20180064667-A1 METHODS OF TREATING LACTOSE INTOLERANCE NOGRA PHARMA LTD (IE) 2018-03-08 US claimed
US-20110152225-A1 PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants NOGRA PHARMA LIMITED (IE) 2011-06-23 US claimed
EP-2131829-A1 PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS Giuliani International Limited (IE) 2009-12-16 EP claimed
US-20090118357-A1 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INTERNATIONAL LIMITED (IE) 2009-05-07 US claimed
WO-2008104557-A1 PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS GIULIANI INTERNATIONAL LIMITED (IE) 2008-09-04 WO claimed
EP-1910275-A2 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD Giuliani International Limited (IE) 2008-04-16 EP claimed
WO-2007010514-A2 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD GIULIANI INTERNATIONAL LIMITED (IE) 2007-01-25 WO claimed
EP-1183260-B1 TRIPHENDIOXAZINE COMPOUNDS CLARIANT FINANCE BVI LTD (VG) 2005-09-28 EP claimed
WO-2003016615-A1 SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES NOVOZYMES NORTH AMERICA, INC. (US) 2003-02-27 WO claimed
JP-2003500408-A 2003-01-07 JP claimed
EP-1183260-A1 TRIPHENDIOXAZINE COMPOUNDS Clariant Finance (BVI) Limited (VG) 2002-03-06 EP claimed
US-6302923-B1 PRINTING OR DYEING TEXTILES WITH TRIAZINE DYES,TRIPHENODIOXAZINE DYES, INK JET INKS FOR PAPER CLARIANT FINANCE (BVI) LIMITED (VG) 2001-10-16 US claimed
WO-2000071545-A1 TRIPHENDIOXAZINE COMPOUNDS CLARIANT FINANCE (BVI) LIMITED (VG) 2000-11-30 WO claimed
EP-0345728-B1 Dye composition for keratinous fiber KAO CORP (JP) 1994-09-14 EP claimed
EP-0166542-B1 TRITERPENYL ESTERS OF ORGANIC ACIDS, PROCESS FOR THEIR PRODUCTION, AND HYPOLIPIDEMIC AGENTS COMPOSED OF THEM AMANO PHARMACEUTICAL CO., LTD. (JP) 1990-08-08 EP claimed
US-4748161-A Triterpenyl esters of organic acids and hypolipidemic agents composed of them AMANO PHARMACEUTICAL CO., LTD. (JP) 1988-05-31 US claimed
EP-0166542-A2 Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them AMANO PHARMACEUTICAL CO., LTD. (JP) 1986-01-02 EP claimed
US-20260138969-A1 TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-05-21 US disclosed
US-4007212-A Novel amide compounds POLAROID CORPORATION (US) 1977-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138969-A1 TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF CASP1, CASP3, BAD ALDH1A1 1186/4885KDM4E 3961/4885MAPT 361/4885
US-20090118357-A1 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field EGFR, ERBB3, FGFR3 ALDH1A1 2287/4885KDM4E 4603/4885MAPT 4833/4885
US-20180064667-A1 METHODS OF TREATING LACTOSE INTOLERANCE LCT, LPL, PPARG ALDH1A1 530/4885KDM4E 4341/4885MAPT 4369/4885
US-20110152225-A1 PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants PPARG, FABP2, PPARD ALDH1A1 983/4885KDM4E 4571/4885MAPT 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.